Olanzapine: A new atypical antipsychotic drug

Neuropsychopharmacology

Volumn 14, Issue 2, 1996, Pages 111-12

  Meltzer, Herbert Y ^a   Christian Fibiger, H ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; MUSCARINIC RECEPTOR; OLANZAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; PIRENZEPINE;

CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; DYSKINESIA; PSYCHOLOGICAL ASPECT; REVIEW;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DYSKINESIA, DRUG-INDUCED; HUMANS; PIRENZEPINE; PSYCHOTIC DISORDERS;

EID: 0029659028     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00197-L     Document Type: Editorial

References (21)

1. Altar CA, Wasley AM, Neale RF, Stone GA (1986): Typical and atypical antipsychotic occupancy of Dz and S2 receptors: An autoradiographic analysis in rat brain. Brain Res Bull 16:517-525
2. Beasley CM, Toleson G, Tran P, Satterlee W, Sanger T, Hamilton S, The Olanzapine HGAD Study Group (1996): Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123
3. Bymaster FP, Calligaro DO, Falcone JF, Marsch RD, Moore NA, Tye NC, Seeman P, Wong DT (1996): Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
4. Chiodo LA, Bunney BS (1983): Typical and atypical neuroleptics differential effects of chronic administration of the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607-1619
5. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psycho- pharmacol 13:25-40
6. Dewey SL, Smith GS, Logan J, Alexoff D, Ding Y-S, King P, Pappas N, Brodie JD, Ashby CR, Jr (1995): Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15:821-829
7. Ichikawa J, Meltzer HY (1990): Apomorphine does not reverse basal dopamine release in rat striatum and nucleus accumbens after chronic haloperidol treatment. Brain Res 507:738-742
8. Liddle PF (1987a): The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br J Psychiatry 151:145-151
9. Liddle PF (1987b): Schizophrenic syndromes, cognitive performance, and neurological dysfunction. Psychol Med 17:49-57
10. Meltzer HY (1995): Clozapine: Is another view valid? (editorial). Am J Psychiatry 152:821-825
11. Meltzer HY (1992): Treatment of neuroleptic non-responsive schizophrenic patient. Schizophr Bull 18:515-542
12. Meltzer H, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J (1989): A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology 99:S68-S72
13. Mereu G, Lilliu V, Vargiu P, Muntoni AL, Diana M, Gessa GL (1994): Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats. Eur J Pharmacol 264:449-453
14. Mesotten F, Suy E, Pictquin M, Burton P, Heylen S, Gelders Y (1989): Therapeutic effect and safety of increasing does of risperidone (R 67 766) in psychotic patients. Psychopharmacology 99:445-449
15. Minabe Y, Ashby CR, Wang RY (1992): Effects produced by acute and chronic treatment with granisetron alone or in combination with haloperidol on midbrain dopamine neurons. Eur Neuropsychopharmacol 2:127-133
16. Rasmussen K, Stockton ME, Czachura JF (1991): The 5-HT3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons. Eur J Pharmacol 205:113-116
17. Robertson GS, Fibiger HC (1996): Effects of olanzapine in regional c-fos expression in rat forebrain. Neuropsychopharmacology 14:105-110
18. Robertson GS, Fibiger HC (1992): Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 46:315-328
19. Robertson, GS, Matsumura H, Fibiger HC (1994): Induction patterns of neuroleptic-induced Foslike immunoreactiv- ity as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058-1066
20. Stockton ME, Rasmussen K (1996): Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14:97-104
21. Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991): Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614